Phase II Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Patients With Advanced Solid Tumors (KEYNOTE 158)
Summary
NOTE: This trial has limited slots available.
The purpose of this phase II trial is to determine the effectiveness of pembrolizumab in patients with multiple types of advanced (unresectable and/or metastatic) solid tumors that have progressed on standard of care therapy and to further evaluate its safety.
Biomarker testing will be done during screening for the trial.
General Information
NCT#: NCT02628067
Study ID: 3475-158
Trial Phase: Phase II
Trial Sponsor: Merck Sharp & Dohme Corp.
Therapies Used in This Trial: Pembrolizumab